ArticleMovement disorders clinical practice2026
Medication Knowledge of Patients with Parkinson's Disease: Strengths and Gaps.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEffective drug treatment of motor and non-motor symptoms in Parkinson's disease (PD) often requires the administration of several anti-Parkinson drugs in complex treatment regimens. The successful autonomous application of drugs places high demands on therapy adherence, which in turn relies on sufficient medication knowledge. However, limited information exists regarding the medication knowledge among PD patients.
objectivesThe aim of this study was to determine the knowledge of PD patients regarding drug treatment, device-aided therapies and to explore potential factors influencing this knowledge.
methodsThe study was conducted as a prospective, cross-sectional, interview-based investigation, enrolling 70 patients. Knowledge on medication was standardized according to the number of drugs taken and expressed as a medication knowledge quotient (MKQ).
resultsThe median MKQ was reasonably high at 4.9 (IQR 3.5-5.9), without influence of sex and disease duration. Increasing age (p = 0.003), decreasing cognitive function (p < 0.001), low educational attainment (p < 0.001) and dispensing responsibility for drug provision (p < 0.001) negatively influenced MKQ. Knowledge regarding anti-Parkinson's drugs (ATC N04) was significantly higher than knowledge of other drug classes (p < 0.001). In contrast, knowledge of device-aided treatment options was poor.
conclusionPD patients displayed a high level of medication knowledge, particularly regarding anti-Parkinson's drugs. Age and the accompanying cognitive impairment had a negative impact on medication knowledge. By contrast, knowledge of the key features of device-aided treatment options requires considerable improvement.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.